文献速递瓣膜病与结构性心脏病

经导管主动脉瓣置换术中脑栓塞保护研究

Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement.
PubMed 文献 · J Am Coll Cardiol · 2016-11-01

多中心随机对照试验纳入363例TAVR患者,评估经导管脑栓塞保护装置的安全性及有效性。主要安全终点MACCE发生率为7.3%,非劣于性能目标18.3%(p<0.001),与对照组9.9%无统计学差异(p=0.41)。主要疗效终点新病灶体积在装置组为102.8 mm³,对照组为178.0 mm³,差异无统计学意义(p=0.33)。

要点

  • TCEP装置在TAVR术中安全,30天MACCE发生率7.3%非劣于预设目标。
  • 装置组新发脑病灶体积102.8 mm³ vs 对照组178.0 mm³,差异无统计学意义。
  • 99%患者滤器内捕获栓塞 debris,包括血栓、钙化、瓣膜组织等。

核心结论

  • TCEP在TAVR术中安全,99%患者捕获栓塞 debris,未改变神经认知功能,但MRI新病灶体积减少无统计学意义。

研究设计与样本

  • 19个中心随机分配363例TAVR患者至安全组(n=123)、装置成像组(n=121)和对照成像组(n=119)。

主要发现

  • MACCE发生率7.3%,非劣于性能目标18.3%(p<0.001),与对照组9.9%无统计学差异(p=0.41)。
  • 新病灶体积装置组102.8 mm³,对照组178.0 mm³(p=0.33)。
  • 30天卒中发生率对照组9.1%,装置组5.6%(p=0.25)。
  • 神经认知功能相似,但病灶体积与神经认知下降相关(p=0.0022)。
  • 99%患者滤器内发现 debris,包括血栓、钙化、瓣膜组织、动脉壁和异物。

临床怎么用

  • TCEP可安全用于TAVR,有效捕获栓塞 debris,但未显著减少MRI新病灶体积。

局限性

  • 主要疗效终点新病灶体积减少未达统计学意义,研究可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neurological complications after transcatheter aortic valve replacement (TAVR) may be reduced with transcatheter cerebral embolic protection (TCEP). OBJECTIVES: This study evaluated the safety and efficacy of TCEP during TAVR. METHODS: Nineteen centers randomized 363 patients undergoing TAVR to a safety arm (n = 123), device imaging (n = 121), and control imaging (n = 119). The primary safety endpoint consisted of major adverse cardiac and cerebrovascular events (MACCE) at 30 days, and the primary efficacy endpoint was reduction in new lesion volume in protected brain territories on magnetic resonance imaging scans at 2 to 7 days. Patients underwent neurocognitive assessments, and the debris captured was analyzed. RESULTS: The rate of MACCE (7.3%) was noninferior to the performance goal (18.3%, pnoninferior < 0.001) and not statistically different from that of the control group (9.9%; p = 0.41). New lesion volume was 178.0 mm3 in control subjects and 102.8 mm3 in the device arm (p = 0.33). A post hoc multivariable analysis identified pre-existing lesion volume and valve type as predictors of new lesion volume. Strokes at 30 days were 9.1% in control subjects and 5.6% in patients with devices (p = 0.25) Neurocognitive function was similar in control subjects and patients with devices, but there was a correlation between lesion volume and neurocognitive decline (p = 0.0022). Debris found within filters in 99% of patients included thrombus, calcification, valve tissue, artery wall, and foreign material. CONCLUSIONS: TCEP was safe, captured embolic debris in 99% of patients, and did not change neurocognitive function. Reduction in new lesion volume on magnetic resonance scans was not statistically significant. (Cerebral Protection in Transcatheter Aortic Valve Replacement [SENTINEL]; NCT02214277).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kapadia SR, Kodali S, Makkar R, et al. Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2016. PMID: 27815101. doi:10.1016/j.jacc.2016.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。